Outcomes17

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 17 of 17

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Clinical Global Impression-Severity-Severe Mood Dysregulation	Baseline through week 12.	Compares groups lisdexamfetamine plus fluoxetine vs. lisdexamfetamine plus placebo over 12 week trial. Some participants discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	ADHD-IV Rating Scale	Baseline through week 12.	Participants discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Conners Parent Global Index	Baseline through week 3.	Participants were assessed on this measure only during the Open Lisdexamfetamine phase. Some participant discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Conners Global Index Emotional Lability Subscale - Parent Report	Baseline to week 3.	Participants were assessed on this measure only during the Open Lisdexamfetamine phase. Some participants discontinues as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Conners Global Index Restless-Impulsive Subscale Parent Report	Baseline through week 3.	Participants were assessed on this measure only during the Open Lisdexamfetamine phase. Some participants discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Conners Teacher Global Index	Baseline through week 3.	Participants were assessed on this measure only during the Open Lisdexamfetamine phase. Some participants discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Affective Reactivity Index - Parent Report	Baseline through week 12.	Some participants discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Revised Modified Overt Aggression Scale - Total Score	Baseline through week 12.	Some participants discontinued as trial progressed.	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Clinical Global Impression - Improvement	Percentage improved at week 4 for Open Lisdexamfetamine group and at week 12 for fluoxetine and placebo groups.	Some participants discontinued as trial progressed.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Height	Baseline through week 12.	Participants discontinued as trial progressed.	cm.	LEAST_SQUARES_MEAN
SECONDARY	Weight	Baseline through week 12.	Some participants discontinued as trial progressed.	kg.	LEAST_SQUARES_MEAN
SECONDARY	Pulse	Baseline through week 12.	Some participants discontinued as trial progressed.	beats per minute.	LEAST_SQUARES_MEAN
SECONDARY	Systolic Blood Pressure	Baseline through week 12.	Some participants discontinued as trial progressed.	mm Hg.	LEAST_SQUARES_MEAN
SECONDARY	Diastolic Blood Pressure	Baseline through week 12.	Some participants discontinued as trial progressed.	mm Hg.	LEAST_SQUARES_MEAN
OTHER_PRE_SPECIFIED	Pediatric Anxiety Rating Scale	Baseline through week 12.
OTHER_PRE_SPECIFIED	Children's Depression Rating Scale	Baseline through week 12.
OTHER_PRE_SPECIFIED	Affective Reactivity Index Child Report	Baseline through week 12.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01714310/outcomes

API reference For AI assistants